Cat.No. : CSC-SC007893 Host Cell: HEK293 (CHO and other cell types are also available)
| Cat. No. | CSC-SC007893 |
| Description | Using Creative Biogene's proprietary lentiviral vectors, we subclone the target gene into lentivector, generate the lentivirus particles, sequentially infect the cell line HEK293 (other cell types are also available according to your requirements), and select the clones constantly expressing target gene at high level. |
| Gene | KARS |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 (CHO and other cell types are also available) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Size Form | 2 × 10^6 cells / vial |
| Shipping | Dry Ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Gene Name | Kars lysyl-tRNA synthetase [ Rattus norvegicus ] |
| Gene Symbol | Kars |
| Gene Description | lysyl-tRNA synthetase |
| Gene ID | 292028 |
| UniProt ID | Q5XIM7 |
| mRNA Refseq | NM_001006967.1 |
| Protein Refseq | NP_001006968.1 |
| Chromosome Location | 19q12 |
| Function | ATP binding; amino acid binding; lysine-tRNA ligase activity; lysine-tRNA ligase activity; magnesium ion binding; tRNA binding; |
| Pathway | Aminoacyl-tRNA biosynthesis, organism-specific biosystem; Aminoacyl-tRNA biosynthesis, conserved biosystem; Aminoacyl-tRNA biosynthesis, eukaryotes, organism-specific biosystem; Aminoacyl-tRNA biosynthesis, eukaryotes, conserved biosystem; Cytosolic tRNA aminoacylation, organism-specific biosystem; Gene Expression, organism-specific biosystem; Mitochondrial tRNA aminoacylation, organism-specific biosystem; |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Chemotherapy resistance is a common phenomenon during conventional treatment (platinum-based chemotherapy) of advanced or recurrent cervical cancer. Here, researchers investigated the effects of tanshinone I on cervical cancer cell proliferation and chemotherapy resistance, as well as its potential mechanisms. Western blot analysis showed that tanshinone I significantly inhibited KRAS expression and suppressed AKT phosphorylation. rVista analysis and luciferase reporter gene assays indicated that ELK1 can directly bind to the KRAS promoter and positively regulate KRAS expression. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays showed that overexpression of KRAS or ELK1 significantly attenuated the inhibitory effect of tanshinone I on HeLa cell proliferation. Furthermore, tanshinone I restored cisplatin sensitivity in HeLa CR cells, while overexpression of KRAS or ELK1 significantly inhibited this effect. These findings suggest that tanshinone I exerts its anti-cancer effects on cervical cancer cells by inhibiting ELK1 and downregulating the KRAS-AKT pathway, thereby suppressing cervical cancer cell proliferation and cisplatin resistance.
Here, researchers constructed a KRAS-overexpressing HeLa cell line (Figure 1A). Figures 1B and 1C show that tanshinone I inhibited the viability of HeLa cells in a time-dependent manner compared to the control group. However, the viability of KRAS- or ELK1-overexpressing HeLa cells was significantly increased compared to the tanshinone I group (Figures 1B and 1C). On the other hand, Figures 5D and 5E show that treatment with 4 μM cisplatin for 5 days had little effect on the viability of cells transfected with empty vector, KRAS-overexpressing HeLa CR cells, or ELK1-overexpressing HeLa CR cells compared to the control group. However, combined treatment with cisplatin and tanshinone I inhibited the viability of HeLa CR cells transfected with empty vector (Figures 1D and 1E). Compared to the vector group, transfection with KRAS or ELK1 overexpression plasmids significantly abolished the inhibitory effect of combined cisplatin and tanshinone I treatment on HeLa CR cell viability (Figures 1D and 1E).
Figure 1. KRAS and ELK1 are the functional downstream effectors of tanshinone I. (Dun S, Gao L., 2019)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
